osimertinib
astrazeneca
[]
absolutely correct. investigators should not have participated in the study if the company did not guarantee that they would give osi to the control arm for free upon metastatic disease which was the us standard of care. #asco23. 
Professor @ucsf, Physician-Scientist, Writer; More at @vkprasadlab @plenary_session, YouTube, #vpzd podcast & @Sensible__Med; Views are mine